Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat strategy (i.e. urodynamics) being cost-effective across different willingness to pay thresholds per additional woman successfully treated.

Acceptability curves of four treatment strategies to be cost-effective versus willingness-to-pay per QALY.

Joyce H. S. You (318736)
Eva S. K. Chan (327943)
Maggie Y. K. Leung (327944)
Margaret Ip (225393)
Nelson L. S. Lee (327947)

February 2013

Acceptability curves of four treatment strategies to be cost-effective versus willingness-to-pay ...

Cost-effectiveness acceptability curves depicting the probability that BASE, INT, and OPT strategies are cost-effective across different threshold values of willingness to pay from 195 2nd order Monte Carlo simulations.

Richard E. Nelson (764526)
Makoto Jones (322757)
Molly Leecaster (488449)
Matthew H. Samore (446720)
William Ray (2586562)
Angela Huttner (408726)
Benedikt Huttner (322756)
Karim Khader (488450)
Vanessa W. Stevens (2586565)
Dale Gerding (2586568)
Marin L. Schweizer (246315)
Michael A. Rubin (322758)

March 2016

Cost-effectiveness acceptability curves depicting the probability that BASE, INT, and OPT strateg...

Cost-effectiveness acceptability curve showing probability that JCP+TAU is more cost-effective than TAU over 18-months follow-up by ethnic group.

Barbara Barrett (489210)
Waquas Waheed (489211)
Simone Farrelly (489212)
Max Birchwood (489213)
Graham Dunn (489214)
Clare Flach (489215)
Claire Henderson (489216)
Morven Leese (489217)
Helen Lester (164644)
Max Marshall (489218)
Diana Rose (342126)
Kim Sutherby (489219)
George Szmukler (489220)
Graham Thornicroft (44441)
Sarah Byford (405086)

November 2013

Cost-effectiveness acceptability curve showing probability that JCP+TAU is more cost-effective th...

Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat strategy being cost-effective across different willingness to pay thresholds per additional woman successfully treated.

Ilias Goranitis (2938686)
Pelham Barton (186762)
Lee J. Middleton (500429)
Jonathan J. Deeks (44965)
Jane P. Daniels (2938680)
Pallavi Latthe (20333)
Arri Coomarasamy (42365)
Suneetha Rachaneni (2938677)
Shanteela McCooty (2938689)
Tina S. Verghese (2938683)
Tracy E. Roberts (381205)

August 2016

Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-t...

Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat strategy being cost-effective across different willingness to pay thresholds per additional quality-adjusted life-year (QALY).

Ilias Goranitis (2938686)
Pelham Barton (186762)
Lee J. Middleton (500429)
Jonathan J. Deeks (44965)
Jane P. Daniels (2938680)
Pallavi Latthe (20333)
Arri Coomarasamy (42365)
Suneetha Rachaneni (2938677)
Shanteela McCooty (2938689)
Tina S. Verghese (2938683)
Tracy E. Roberts (381205)

August 2016

Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-t...

Cost-effectiveness acceptability frontier (CEAF) showing the probability of the optimal intervention being cost-effective at 12 months from a NHS/PSS perspective across different willingness-to-pay values per additional quality-adjusted life-year (QALY).

Ilias Goranitis (2938686)
Leana Bellanca (4471075)
Amanda J. Daley (4471069)
Adele Thomas (4471072)
Helen Stokes-Lampard (4471066)
Andrea K. Roalfe (4471063)
Sue Jowett (762813)

September 2017

Cost-effectiveness acceptability frontier (CEAF) showing the probability of the optimal intervent...

Probability of being most cost-effective at any given threshold, considering high-efficacy sustained vector control and a highly targeted, low-cost immunization strategy.

Christopher Fitzpatrick (157320)
Alexander Haines (4354174)
Mathieu Bangert (178674)
Andrew Farlow (4238818)
Janet Hemingway (23878)
Raman Velayudhan (341226)

August 2017

The solid lines are cost-effectiveness acceptability curves (CEACs) representing the probability ...

Cost-effectiveness acceptability curves (CEACs) showing the probability that each of the treatment options is optimal, subject to a range of ceiling ratios, which represent the maximum amount society would pay for a one unit improvement in QALYs.

Elizabeth A. Barley (573572)
Paul Walters (349725)
Mark Haddad (469281)
Rachel Phillips (469282)
Evanthia Achilla (573573)
Paul McCrone (121370)
Harm Van Marwijk (573574)
Anthony Mann (469284)
Andre Tylee (3146625)

June 2014

Cost-effectiveness acceptability curves (CEACs) showing the probability that each of the treatmen...

Cost-effectiveness acceptability curve (CEAC) showing probability for the program to be cost-effective at different WTP.

Malin Ulfsdotter (838295)
Lene Lindberg (838296)
Anna Månsdotter (838297)

December 2015

Cost-effectiveness acceptability curve (CEAC) showing probability for the program to be cost-effe...

Cost-effectiveness Acceptability Frontier and Expected Value of Perfect Information.

Elena Losina (195874)
Elizabeth E. Dervan (757218)
A. David Paltiel (234682)
Yan Dong (135314)
R. John Wright (757219)
Kurt P. Spindler (757220)
Lisa A. Mandl (757221)
Morgan H. Jones (757222)
Robert G. Marx (757223)
Clare E. Safran-Norton (757224)
Jeffrey N. Katz (195870)

June 2015

Fig 4 contains two categories of reported results. The first is the cost-effectiveness acceptabil...

Probability that specialist clinics are cost-effective for a range of willingness to pay thresholds.

David Brain (848856)
Ruth Tulleners (6429230)
Xing Lee (6289946)
Qinglu Cheng (5350244)
Nicholas Graves (258283)
Rosana Pacella (5350247)

March 2019

Probability that specialist clinics are cost-effective for a range of willingness to pay thresholds....

Cost-effectiveness acceptability curves showing the probability that PCM plus TENS is cost effective across different willingness-to-pay threshold values.

Martyn Lewis (789657)
Linda S. Chesterton (789658)
Julius Sim (41526)
Christian D. Mallen (633500)
Elaine M. Hay (718524)
Daniëlle A. van der Windt (2209042)

August 2015

Cost-effectiveness acceptability curves showing the probability that PCM plus TENS is cost effect...

Cost-effectiveness acceptability curve showing the probability that golimumab with standard care is cost-effective versus standard care alone at a range of different threshold values.

Ewa Stawowczyk (30350)
Paweł Kawalec (467764)
Andrzej Pilc (467767)

August 2016

Cost-effectiveness acceptability curve showing the probability that golimumab with standard care ...

Cost effectiveness acceptability curve (CEAC) for the probabilistic sensitivity analysis for 10,000 simulations across a range of willingness to pay values for the QALY.

Rashidah T. Uthman (4789503)
Andrew J. Sutton (813522)
Louise J. Jackson (4789500)
Olalekan A. Uthman (321580)

January 2018

Cost effectiveness acceptability curve (CEAC) for the probabilistic sensitivity analysis for 10,0...

Cost-effectiveness acceptability curve.

Surasak Saokaew (551387)
Wichittra Tassaneeyakul (551388)
Ratree Maenthaisong (551389)
Nathorn Chaiyakunapruk (551390)

April 2014

The curves provide the probability of the different strategy being the most cost-effective option...

Acceptability curves of four treatment strategies to be cost-effective versus willingness-to-pay per QALY.

Joyce H. S. You (318736)
Eva S. K. Chan (327943)
Maggie Y. K. Leung (327944)
Margaret Ip (225393)
Nelson L. S. Lee (327947)

February 2013

Acceptability curves of four treatment strategies to be cost-effective versus willingness-to-pay ...

Cost-effectiveness acceptability curves depicting the probability that BASE, INT, and OPT strategies are cost-effective across different threshold values of willingness to pay from 195 2nd order Monte Carlo simulations.

Richard E. Nelson (764526)
Makoto Jones (322757)
Molly Leecaster (488449)
Matthew H. Samore (446720)
William Ray (2586562)
Angela Huttner (408726)
Benedikt Huttner (322756)
Karim Khader (488450)
Vanessa W. Stevens (2586565)
Dale Gerding (2586568)
Marin L. Schweizer (246315)
Michael A. Rubin (322758)

March 2016

Cost-effectiveness acceptability curves depicting the probability that BASE, INT, and OPT strateg...

Cost-effectiveness acceptability curve showing probability that JCP+TAU is more cost-effective than TAU over 18-months follow-up by ethnic group.

Barbara Barrett (489210)
Waquas Waheed (489211)
Simone Farrelly (489212)
Max Birchwood (489213)
Graham Dunn (489214)
Clare Flach (489215)
Claire Henderson (489216)
Morven Leese (489217)
Helen Lester (164644)
Max Marshall (489218)
Diana Rose (342126)
Kim Sutherby (489219)
George Szmukler (489220)
Graham Thornicroft (44441)
Sarah Byford (405086)

November 2013

Cost-effectiveness acceptability curve showing probability that JCP+TAU is more cost-effective th...

Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat strategy being cost-effective across different willingness to pay thresholds per additional woman successfully treated.

Ilias Goranitis (2938686)
Pelham Barton (186762)
Lee J. Middleton (500429)
Jonathan J. Deeks (44965)
Jane P. Daniels (2938680)
Pallavi Latthe (20333)
Arri Coomarasamy (42365)
Suneetha Rachaneni (2938677)
Shanteela McCooty (2938689)
Tina S. Verghese (2938683)
Tracy E. Roberts (381205)

August 2016

Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-t...

Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat strategy being cost-effective across different willingness to pay thresholds per additional quality-adjusted life-year (QALY).

Ilias Goranitis (2938686)
Pelham Barton (186762)
Lee J. Middleton (500429)
Jonathan J. Deeks (44965)
Jane P. Daniels (2938680)
Pallavi Latthe (20333)
Arri Coomarasamy (42365)
Suneetha Rachaneni (2938677)
Shanteela McCooty (2938689)
Tina S. Verghese (2938683)
Tracy E. Roberts (381205)

August 2016

Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-t...

Cost-effectiveness acceptability frontier (CEAF) showing the probability of the optimal intervention being cost-effective at 12 months from a NHS/PSS perspective across different willingness-to-pay values per additional quality-adjusted life-year (QALY).

Ilias Goranitis (2938686)
Leana Bellanca (4471075)
Amanda J. Daley (4471069)
Adele Thomas (4471072)
Helen Stokes-Lampard (4471066)
Andrea K. Roalfe (4471063)
Sue Jowett (762813)

September 2017

Cost-effectiveness acceptability frontier (CEAF) showing the probability of the optimal intervent...

Probability of being most cost-effective at any given threshold, considering high-efficacy sustained vector control and a highly targeted, low-cost immunization strategy.

Christopher Fitzpatrick (157320)
Alexander Haines (4354174)
Mathieu Bangert (178674)
Andrew Farlow (4238818)
Janet Hemingway (23878)
Raman Velayudhan (341226)

August 2017

The solid lines are cost-effectiveness acceptability curves (CEACs) representing the probability ...

Cost-effectiveness acceptability curves (CEACs) showing the probability that each of the treatment options is optimal, subject to a range of ceiling ratios, which represent the maximum amount society would pay for a one unit improvement in QALYs.

Elizabeth A. Barley (573572)
Paul Walters (349725)
Mark Haddad (469281)
Rachel Phillips (469282)
Evanthia Achilla (573573)
Paul McCrone (121370)
Harm Van Marwijk (573574)
Anthony Mann (469284)
Andre Tylee (3146625)

June 2014

Cost-effectiveness acceptability curves (CEACs) showing the probability that each of the treatmen...

Cost-effectiveness acceptability curve (CEAC) showing probability for the program to be cost-effective at different WTP.

Malin Ulfsdotter (838295)
Lene Lindberg (838296)
Anna Månsdotter (838297)

December 2015

Cost-effectiveness acceptability curve (CEAC) showing probability for the program to be cost-effe...

Cost-effectiveness Acceptability Frontier and Expected Value of Perfect Information.

Elena Losina (195874)
Elizabeth E. Dervan (757218)
A. David Paltiel (234682)
Yan Dong (135314)
R. John Wright (757219)
Kurt P. Spindler (757220)
Lisa A. Mandl (757221)
Morgan H. Jones (757222)
Robert G. Marx (757223)
Clare E. Safran-Norton (757224)
Jeffrey N. Katz (195870)

June 2015

Fig 4 contains two categories of reported results. The first is the cost-effectiveness acceptabil...

Probability that specialist clinics are cost-effective for a range of willingness to pay thresholds.

David Brain (848856)
Ruth Tulleners (6429230)
Xing Lee (6289946)
Qinglu Cheng (5350244)
Nicholas Graves (258283)
Rosana Pacella (5350247)

March 2019

Probability that specialist clinics are cost-effective for a range of willingness to pay thresholds....

Cost-effectiveness acceptability curves showing the probability that PCM plus TENS is cost effective across different willingness-to-pay threshold values.

Martyn Lewis (789657)
Linda S. Chesterton (789658)
Julius Sim (41526)
Christian D. Mallen (633500)
Elaine M. Hay (718524)
Daniëlle A. van der Windt (2209042)

August 2015

Cost-effectiveness acceptability curves showing the probability that PCM plus TENS is cost effect...

Cost-effectiveness acceptability curve showing the probability that golimumab with standard care is cost-effective versus standard care alone at a range of different threshold values.

Ewa Stawowczyk (30350)
Paweł Kawalec (467764)
Andrzej Pilc (467767)

August 2016

Cost-effectiveness acceptability curve showing the probability that golimumab with standard care ...

Cost effectiveness acceptability curve (CEAC) for the probabilistic sensitivity analysis for 10,000 simulations across a range of willingness to pay values for the QALY.

Rashidah T. Uthman (4789503)
Andrew J. Sutton (813522)
Louise J. Jackson (4789500)
Olalekan A. Uthman (321580)

January 2018

Cost effectiveness acceptability curve (CEAC) for the probabilistic sensitivity analysis for 10,0...

Cost-effectiveness acceptability curve.

Surasak Saokaew (551387)
Wichittra Tassaneeyakul (551388)
Ratree Maenthaisong (551389)
Nathorn Chaiyakunapruk (551390)

April 2014

The curves provide the probability of the different strategy being the most cost-effective option...

Acceptability curves of four treatment strategies to be cost-effective versus willingness-to-pay per QALY.

Joyce H. S. You (318736)
Eva S. K. Chan (327943)
Maggie Y. K. Leung (327944)
Margaret Ip (225393)
Nelson L. S. Lee (327947)

February 2013

Acceptability curves of four treatment strategies to be cost-effective versus willingness-to-pay ...

Cost-effectiveness acceptability curves depicting the probability that BASE, INT, and OPT strategies are cost-effective across different threshold values of willingness to pay from 195 2nd order Monte Carlo simulations.

Richard E. Nelson (764526)
Makoto Jones (322757)
Molly Leecaster (488449)
Matthew H. Samore (446720)
William Ray (2586562)
Angela Huttner (408726)
Benedikt Huttner (322756)
Karim Khader (488450)
Vanessa W. Stevens (2586565)
Dale Gerding (2586568)
Marin L. Schweizer (246315)
Michael A. Rubin (322758)

March 2016

Cost-effectiveness acceptability curves depicting the probability that BASE, INT, and OPT strateg...

Cost-effectiveness acceptability curve showing probability that JCP+TAU is more cost-effective than TAU over 18-months follow-up by ethnic group.

Barbara Barrett (489210)
Waquas Waheed (489211)
Simone Farrelly (489212)
Max Birchwood (489213)
Graham Dunn (489214)
Clare Flach (489215)
Claire Henderson (489216)
Morven Leese (489217)
Helen Lester (164644)
Max Marshall (489218)
Diana Rose (342126)
Kim Sutherby (489219)
George Szmukler (489220)
Graham Thornicroft (44441)
Sarah Byford (405086)

November 2013

Cost-effectiveness acceptability curve showing probability that JCP+TAU is more cost-effective th...

Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat strategy (i.e. urodynamics) being cost-effective across different willingness to pay thresholds per additional woman successfully treated.

Abstract

Extracted data

Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat strategy (i.e. urodynamics) being cost-effective across different willingness to pay thresholds per additional woman successfully treated.

Abstract

Extracted data

Related items

Related items